Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron vs Granisetron for PONV Prophylaxis in Scoliosis Surgery
NCT06540885Phase 4Completed
- Sponsor
- Universiti Malaya
- Start
- Jan 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Palonosetron Group with Granisetron Group (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting at 48 hours. Started Jan 2025; status: completed.
02
Drugs
palonosetrongranisetron
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06540885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540885.